Journal of Medical Toxicology Systematic Review of 24 Reports Sorts Kratom-Associated Lung Injury Into Five Provisional Categories, Finds Single-Agent Fatalities Had Mitragynine Blood Levels of 2,325 to 7,500 ng/mL, and Urges Clinicians to Consider Kratom and 7-OH in Unexplained Acute Lung Injury
A systematic review published online August 27, 2026 in the Journal of Medical Toxicology identified 24 human reports of pulmonary outcomes after exposure to kratom, mitragynine, or 7-hydroxymitragynine (7-OH), 14 clinical and 10 forensic, and grouped them into five provisional categories: diffuse alveolar hemorrhage, acute respiratory distress syndrome or diffuse acute lung injury, eosinophilic or hypersensitivity pneumonitis, central respiratory depression, and post-mortem pulmonary edema or congestion. Authors Venkatkiran Kanchustambham and Swetha Saladi of Sanford Health and the University of North Dakota School of Medicine reported that all clinical patients survived, all forensic decedents died, causality was graded probable in nine reports and possible in 13, and single-agent fatalities showed mitragynine concentrations of 2,325 to 7,500 ng/mL. The authors describe the categories as hypothesis-generating and call for targeted toxicology and standardized reporting; the abstract notes rising use of concentrated 7-OH products but does not break out findings by product type.
A systematic review published online August 27, 2026 in the Journal of Medical Toxicology has pulled together every published human report the authors could find of lung outcomes following exposure to kratom, mitragynine, or 7-hydroxymitragynine (7-OH), and proposed a five-category framework for classifying them. The authors, Venkatkiran Kanchustambham and Swetha Saladi, are pulmonary and critical care physicians at Sanford Health in Fargo, North Dakota, with appointments at the University of North Dakota School of Medicine and Health Sciences, according to the paper's PubMed record. They write in the abstract that kratom use has increased, "including concentrated 7-hydroxymitragynine products," and that pulmonary toxicity "has not been systematically synthesized."
What the review found
The authors searched five databases through June 24, 2026 for case reports, conference abstracts, and forensic or autopsy series, with the protocol registered in PROSPERO as CRD420261427143. Two reviewers screened and extracted the reports independently, and causality was graded using the Naranjo criteria for clinical reports and the World Health Organization-Uppsala Monitoring Centre criteria for forensic reports. Twenty-four reports met inclusion: 14 clinical and 10 forensic.
The five categories fall into two tiers, according to the abstract. Three are primary pulmonary syndromes: diffuse alveolar hemorrhage (three reports), acute respiratory distress syndrome or diffuse acute lung injury (three), and eosinophilic or hypersensitivity pneumonitis (two). Two are secondary consequences of systemic toxicity: central respiratory depression (six) and post-mortem pulmonary edema or congestion (ten). All of the clinical patients survived, and all of the forensic decedents died. The authors graded attribution to kratom as probable in nine reports, possible in 13, and unlikely in two.
Pulmonary edema and congestion was the most common forensic finding but, the authors note, a nonspecific one. Where a death involved kratom as the only agent, mitragynine blood concentrations were high, ranging from 2,325 to 7,500 ng/mL per the abstract. The paper does not report how many of the 24 cases involved natural leaf kratom versus concentrated extracts or synthetic 7-OH preparations, and the abstract's mention of concentrated 7-OH products appears in the introduction rather than the results. Readers weighing the findings against the current regulatory focus on concentrated and synthetic 7-OH should note that gap.
The authors' conclusions
Kanchustambham and Saladi describe the five categories as "provisional, hypothesis-generating" and stop short of claiming a defined toxidrome. Their clinical recommendation is for physicians to "consider kratom and 7-hydroxymitragynine in unexplained acute lung injury, alveolar hemorrhage, eosinophilic pneumonitis, or opioid-type respiratory depression," and their research recommendation is for "targeted toxicology and standardized reporting" to refine the framework.
The review appears in the same journal, one day after, the American College of Medical Toxicology's position statement on 7-OH and other kratom-associated compounds, which called for restricting nonprescription sales of concentrated 7-OH products. It joins a run of recent pharmacovigilance work on kratom alkaloids that includes a medRxiv preprint reporting a ventricular arrhythmia signal for mitragynine in FDA adverse-event data. Case-report synthesis of this kind cannot establish incidence, and the authors' causality grading, with more than half of reports rated only possible, reflects that limit.
The authors' home state offers its own context. North Dakota regulators cited kratom-associated deaths in emergency rules over the summer, and Governor Kelly Armstrong signed a synthetic kratom ban on September 8 after the House rejected a total ban. The review does not mention the North Dakota debate, and the paper carries no funding or conflict disclosures in the abstract text available through Crossref.
The same clinical instinct, detecting kratom exposure through symptoms that do not fit the presumed product, surfaced this week in Virginia, where the Blue Ridge Poison Center reported finding unlabeled kratom in cat's claw products after patients presented with unexpected symptoms.
Sources
-
Kratom-Associated Pulmonary Toxicity: A Systematic Review of Case Reports and Forensic Series with a Proposed Clinical Phenotype Classification
Journal of Medical Toxicology
Twenty-four reports were included: 14 clinical and 10 forensic. Five categories were identified in two tiers. All clinical patients survived; all forensic decedents died. Attribution was Probable in 9 reports, Possible in 13, and Unlikely in 2. Single-agent fatalities had high mitragynine concentrations (2,325 to 7,500 ng/mL).
-
Kratom-Associated Pulmonary Toxicity: A Systematic Review (PubMed record 42661120)
PubMed
PubMed record listing the authors' affiliations with Pulmonary and Critical Care Medicine at Sanford Health in Fargo, North Dakota and the University of North Dakota School of Medicine and Health Sciences.